Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

Blood

Volumn 111, Issue 10, 2008, Pages 5142-5151

  Col, Jessica Dal ^a   Zancai, Paola ^a   Terrin, Liliana ^b   Guidoboni, Massimo ^a   Ponzoni, Maurilio ^c   Pavan, Alessandro ^a   Spina, Michele ^a   Bergamin, Stefano ^a   Rizzo, Silvana ^a   Tirelli, Umberto ^a   De Rossi, Anita ^b   Doglioni, Claudio ^c   Dolcetti, Riccardo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CD40 ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; INTERLEUKIN 4; MAMMALIAN TARGET OF RAPAMYCIN; PROTEASOME; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; TELOMERASE; CELL CYCLE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PTEN PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; APOPTOSIS; CELL CULTURE; CELL PROLIFERATION; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CELL CYCLE PROTEINS; CELL PROLIFERATION; DOWN-REGULATION; ENZYME ACTIVATION; HUMANS; LYMPHOMA, MANTLE-CELL; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; TUMOR CELLS, CULTURED;

EID: 46749155539     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-07-103481     Document Type: Article

References (50)

1. Carnpo E, Raff eld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115-127.
2. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994;84:2726- 2732.
3. Jadayel DM, Lukas J, Nacheva E, et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia. 1997; 11: 64-72.
4. Gronbaek K, Zeuthen J, Guldberg P, Ralfkiaer E, Hou-Jensen K. Alterations of the MMAG1 /PTEN gene in lymphoid malignancies. Blood. 1998;91: 4388-4390.
5. Ghobrial IM, McCormick DJ, Kaufmann SH, et al. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood. 2005;105:3722-3730.
6. Martinez N, Camacho Fl, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res. 2003;63:8226-8232.
7. Mills GB, Lu Y, Fang X, et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol. 2001 ;28:125-141.
8. Vazquez F, Ramaswamy S, Nakamura N. Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol. 2000; 20:5010-5018.
9. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem. 2001 ;276:48627-48630.
10. Birle D, Bottini N, Williams S, et al. Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. J Immunol. 2002;169:286-291.
11. Viglietto G, Motti ML Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt- mediated phosphorylation in breast cancer. Nat Med. 2002;8:1136-1144.
12. Diehl JA, Cheng M, Roussel MR Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499-3511.
13. Haendeler J, Hoffmann J, Rahman S, Zeiher AM, Dimmeler S. Regulation of telomerase activity and anti-apoptotic function by protein-protein interaction and phosphorylation. FEBS Lett. 2003; 536:180-186.
14. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10:457-468.
15. Gingras AC, Raught B, Sonenberg N. mTOR signaling to translation. Gurr Top Microbiol Immunol. 2004:279:169-197.
16. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455-7464.
17. Kim D, Dan HC, Park S, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 2005;10:975-987.
18. Cully M, You H, LevineAJ, MakTW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6:184-192.
19. Hipp S, Ringshausen L Oelsner M, Bogner G, Peschel G, Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica. 2005;90:1433-1434.
20. Rizzatti EG. Falcao RP, Panepucci RA. et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT WNT and TGFbeta signalling pathways. Br J Haematol. 2005;130: 516-526.
21. Amin HM. McDonnell TJ, Medeiros LJ, et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 2003;127:424-431.
22. Guidoboni M, Zancai P, Cariati R, et al. Retinoic acid inhibits the proliferative response induced by CD40 activation and lnterleukin-4 in mantle cell lymphoma. Cancer Res. 2005;65:587-595.
23. Lyons AB. Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994;171:131-137.
24. Pomponi F, Cariati R, Zancai P, et al. Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood. 1996; 88:3147-3158.
25. Cariati R, Zancai P, Quaia M, et al. Retinoic acid induces persistent, RARα-mediated antiproliferative responses in Epstein-Barr virus- immortalized B lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines. Int J Cancer. 2000;86:375-384.
26. Ballon G, Ometto L, Righetti E et al. Human immunodeficiency virus type 1 modulates telomerase activity in pheripheral blood lymphocytes. J Infect Dis. 2001;183:417-424.
27. Trentin L Ballon G, Ometto L et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol. 1999;106:662-668.
28. Edinger AL Linardic GM, Chiang GG, Thompson CB, Abraham RT. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 2003; 63:8451-8460.
29. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159- 168.
30. Garcia A, Cayla X; Guergnon J, et al. Serine/ threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie. 2003;85: 721-726.
31. Dong J, Peng J, Zhang H, et al. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res. 2005;65:1961-1972.
32. Akiyama M, HideshimaT, Hayashi T et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002;62: 3876-3882.
33. Kimura A, Ohmichi M. Kawagoe J, et al. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene. 2004;23:4505-4515.
34. Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006;108:1668-1676.
35. Peponi E, Drakos E, Reyes G, Leventaki V; Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol. 2006; 169:2171-2180.
36. Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol. 2005; 205:498-506.
37. Rassidakis GZ, Feretzaki M, Atwell C, et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood. 2005;105:827-829.
38. Cheong JW, Eom Jl, Maeng HY, et al. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol. 2003;122:454-456.
39. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB. Younes A. Inhibition of the phosphatidyl- inositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol. 2006;132:503-511.
40. Andersen NS. Larsen JK, Christiansen J. et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood. 2000;96:2219-2225.
41. Ott MM, Bartkova J, Bartek J, et al. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood. 1997;90:3154- 3159.
42. Doglioni C, Chiarelli C, Macri E, et al. Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol. 1998;185:159-166.
43. Medema RH. Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 2000;404:782-787.
44. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002:8:1153-1160.
45. Carrano AC, Eytan E. Hershko A, Pagano M, SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999; 1:193-199.
46. Ganoth D, Bornstein G, Ko TK. et al. The cell- cycle regulatory protein Cks1 is required for SCF- (Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol. 2001;3:321-324.
47. Spruck C, Strohmaier H. Watson M, et al. ACDK- independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell. 2001;7:639-650.
48. Min YH, Cheong JW, Lee MH, et al. Elevated S- phase kinase-associated protein 2 protein expression in acute myelogenous leukemia: its association with constitutive phosphorylation of phosphatase and tensin homologue protein and poor prognosis. Clin Cancer Res. 2004;10:5123- 5130.
49. Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem. 1999;274: 13085-13090.
50. Bae-Jump VL, Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest. Gynecol Oncol. 2006;100:487-494.